Search

everythinglearnresearchcommunity

for

Search:↓

Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.

Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.

Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.

Methotrexate with steroids is slightly more effective than azathioprine with steroids for treating severe alopecia areata.

Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Weekly Azathioprine Pulse therapy is more effective than Betamethasone Oral Mini-Pulse for hair regrowth in moderate to severe Alopecia Areata.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

CTP-543 is generally safe for treating alopecia areata.

Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Intralesional triamcinolone acetonide is more effective but has a higher relapse rate than platelet-rich plasma for treating alopecia areata.

Having asthma, atopic dermatitis, or Hashimoto's thyroiditis increases the risk of severe and long-lasting alopecia areata.

Early diagnosis and multidisciplinary care, including orthopedic surgery, can prevent long-term disability in IFAP syndrome.

JAK inhibitors and platelet-rich plasma show promise for treating alopecia areata.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.